Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + TP Neoadjuvant for Stage IVB OSCC
NCT06277791Phase 2Recruiting
- Start
- Aug 2023
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in oral squamous cell carcinoma (OSCC). Started Aug 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
oral squamous cell carcinoma (OSCC)
Beyond the preview
Go deeper on NCT06277791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06277791.